IrelandIreland

Elan Sells Swiss and Italian Sites

05.02.2004

Dublin - The Irish biopharmaceutical group Elan has raised some $70 million from new deals and milestone payments. Elan received $25 million from King Pharmaceuticals for renewing patent exclusivity for Skelaxin (metaxalone) a small molecule drug against acute, painful musculoskeletal conditions. Additionally Elan agreed to sell Elan Pharma SA, a manufacturing and R&D business in Mezzovicco, Switzerland, to affiliates of the U.S. investment bank Sanders Morris Harris. Finally Elan also sold the manufacturing business of Segix Italia to a management buyout team. Elan President and CEO Kelly Martin said, “These transactions are consistent with our strategy of focusing our resources on our core therapeutic focus areas” in neurology, pain management and autoim-mune diseases.

IrelandIreland

17.12.2009

Dublin – Irish company Elan Corporation plc and its partner Transition Therapeutics have withdrawn patients from two ongoing phase II trials with the compound ELDN005 following the death of nine patients. The studies were stopped...

IrelandIreland

14.10.2009

Dublin – Amarin Corporation plc today announced it has entered into an agreement with a number of investors for a $70 million private placement. The placement of units for $70 million consists of $66.4 million in cash proceeds...

IrelandIreland

19.09.2009

Dublin – The Republic of Ireland has amended its patent law to bring it into line with the rest of Europe and make its domestic patenting system more straightforward. The government said increased levels of research in Ireland in...

IrelandIreland

10.08.2009

Dublin - The honeymoon between Elan and Biogen has been over for a long time, now the marriage of the Irish biotech company and their US partner lies in ruins. The Elan Corporation has filed suit against Biogen Idec Inc. In the...

IrelandIreland

12.07.2009

Dublin – Ireland is focussing on expanding productivity in the upstream processing of biological drugs. Science Minister Conor Lenihan has announced EUR2.3m in funding for the next 3 years aimed at delivering more efficient and...

IrelandIreland

07.07.2009

Dublin/New Brunswick – Pharma giant Johnson &Johnson will buy all assets of Irish Elan Pharmaceuticals’ Alzheimer’s Immunotherapy Programme (AIP) through a newly formed company. The new company will pay $1 billion for an 18.4%...

IrelandIreland

17.06.2009

Dublin – Trinity College of Dublin's Institute of Molecular Medicine has opened Ireland´s first next generation DNA sequencing facility. The platform, built upon the current market-leading “Illumina Genome Analyzer II“ platform,...

IrelandIreland

14.06.2009

Dublin – Trinity College Dublin spin-out Opsona Therapeutics, a specialist in autoimmune and inflammatory diseases, has announced that the Roche Venture Fund and Enterprise Ireland have committed an additional EUR3.3m to the...

IrelandIreland

22.04.2009

Dublin – Ireland fears growing rates of resistant pneumococcus in the country's hospitals. A recent report by the Health Protection Surveillance Centre (HSPC) shows that 32% of 124 clinical isolates tested were non-susceptible to...

IrelandIreland

31.10.2008

Cork – Ireland is set to lose another 180 pharma jobs after pharmaceutical giant Pfizer announced it had failed to find a buyer for one of its five manufacturing facilities in the country. For the past 18 months, the company has...

Displaying results 21 to 30 out of 49

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-ireland/browse/2/article/elan-sells-swiss-and-italian-sites.html

Events

All Events

Stock list

All quotes

TOP

  • WILEX2.69 EUR14.47%
  • BAYER112.70 EUR6.17%
  • CO.DON3.32 EUR5.40%

FLOP

  • SYNGENTA310.90 CHF-1.96%
  • SANTHERA88.05 CHF-1.23%
  • ADDEX3.10 CHF-0.96%

TOP

  • CO.DON3.32 EUR32.8%
  • PAION3.05 EUR27.1%
  • EPIGENOMICS3.83 EUR22.8%

FLOP

  • ADDEX3.10 CHF-22.5%
  • EVOTEC3.08 EUR-16.1%
  • MEDIGENE3.93 EUR-14.6%

TOP

  • SANTHERA88.05 CHF2058.1%
  • CO.DON3.32 EUR277.3%
  • PAION3.05 EUR202.0%

FLOP

  • CYTOS0.24 CHF-94.0%
  • THERAMETRICS0.09 CHF-40.0%
  • BIOFRONTERA2.20 EUR-39.7%

No liability assumed, Date: 18.09.2014


Current issue

All issues

Product of the week

Products